Thomas E Darcy's most recent trade in Viracta Therapeutics Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics Inc | Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
Viracta Therapeutics Inc | Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
Viracta Therapeutics Inc | Thomas E. Darcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
Forte Biosciences Inc | Thomas E. Darcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.59 per share. | 13 Jan 2021 | 500 | 2,358 | - | 9.6 | 4,793 | Common Stock |
Forte Biosciences Inc | Thomas E. Darcy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 500 | 0 | - | - | Stock Option (right to buy) |